First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
-
Published:2020-12
Issue:
Volume:54
Page:256-263
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Hardy-Bessard Anne-Claire,
Brocard Fabien,
Clatot Florian,
Lortholary Alain,
You Benoît,
Grenier Julien,
Martin-Babau Jérôme,
Lucas Brigitte,
Meunier Jérôme,
Ferrero Jean-Marc,
Savoye Aude-Marie,
Marti Adina,
Despax Raymond,
Moullet Isabelle,
Emile GeorgeORCID
Subject
General Medicine,Surgery
Reference35 articles.
1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007
2. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010
3. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011
4. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation;Miles;Eur J Canc,2017
5. Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN);Schilling;Curr Med Res Opin,2019
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献